Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 Dec 24;9(1):28. doi: 10.3390/plants9010028

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2019 by the authors.

Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).

PMC Copyright notice

Effects of myricetin and cisplatin on MDA, MPO and nitrite levels. (a) In cisplatin-treated group II, the MDA level increased significantly (*** p < 0.001) as compared to control group I. Pre-treatment with and myricetin (25 and 50 mg/kg b. wt.) significantly attenuated the MDA level in group III (# p < 0.05) and group IV (### p < 0.001) when compared to group II. (b) In cisplatin-treated group II, the MPO level (Leukocyte infiltration) increased significantly (*** p < 0.001) as compared to control group I. Pre-treatment with myricetin (25 and 50 mg/kg b. wt.) significantly attenuated the MPO level in group III (# p < 0.05) and group IV (## p < 0.01) as compared to group II. (c) In cisplatin-treated group II, the nitrite levels were significantly increased (*** p < 0.001) as compared to control group I. Pre-treatment with myricetin significantly (25 and 50 mg/kg b. wt.) attenuated the nitrite levels in group III (## p < 0.01) and group IV (## p < 0.001) as compared to group II.

Effects of myricetin and cisplatin on MDA, MPO and nitrite levels. (a) In cisplatin-treated group II, the MDA level increased significantly (*** p < 0.001) as compared to control group I. Pre-treatment with and myricetin (25 and 50 mg/kg b. wt.) significantly attenuated the MDA level in group III (# p < 0.05) and group IV (### p < 0.001) when compared to group II. (b) In cisplatin-treated group II, the MPO level (Leukocyte infiltration) increased significantly (*** p < 0.001) as compared to control group I. Pre-treatment with myricetin (25 and 50 mg/kg b. wt.) significantly attenuated the MPO level in group III (# p < 0.05) and group IV (## p < 0.01) as compared to group II. (c) In cisplatin-treated group II, the nitrite levels were significantly increased (*** p < 0.001) as compared to control group I. Pre-treatment with myricetin significantly (25 and 50 mg/kg b. wt.) attenuated the nitrite levels in group III (## p < 0.01) and group IV (## p < 0.001) as compared to group II.